Aflibercept Mechanism of Action: How Aflibercept Works | Elicit

Aflibercept Mechanism of Action

How Aflibercept (Eylea) Works: Soluble decoy receptor binding VEGF-A/PlGF to inhibit VEGF receptor activation and reduce neovascularization and vascular permeability.

Quick Summary

Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor. It binds VEGF-A and placental growth factor (PlGF), inhibiting activation of VEGF receptors that can drive neovascularization and vascular permeability. Clinically, this anti-VEGF mechanism supports treatment of retinal conditions such as neovascular (wet) AMD, macular edema after retinal vein occlusion, and diabetic macular edema/diabetic retinopathy.

Properties

Details
Generic Name Aflibercept
Brand Names Eylea
Drug Class Vascular endothelial growth factor (VEGF) inhibitor
Primary Target Vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and vascular endothelial growth factor receptor 2 (VEGFR-2; KDR)
Approved Indications Neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), myopic choroidal neovascularization
Key Effect Inhibits VEGF-A/PlGF signaling to reduce VEGF receptor activation, neovascularization, and vascular permeability

Development History

Aflibercept was developed by Regeneron Pharmaceuticals in collaboration with Bayer, emerging from Regeneron's internal VEGF Trap program in the early 2000s. The molecule is a recombinant fusion protein engineered as a soluble decoy receptor...

The first FDA approval program was built on two parallel Phase 3 trials: VIEW 1 (1,217 patients, North America) and VIEW 2 (1,240 patients, international). Each randomized patients with active subfoveal choroidal neovascularization due to wet AMD to one of four arms—aflibercept 0.5 mg monthly, 2 mg monthly, or 2 mg every 8 weeks after three loading doses, versus ranibizumab 0.5 mg monthly...

Detailed Mechanism of Action

Fusion protein architecture and distribution.

Aflibercept is a fully human soluble decoy receptor comprising the second immunoglobulin (Ig) domain of human VEGFR1 and the third Ig domain of human VEGFR2 fused inline to the constant Fc region of human IgG1.

Primary molecular target and the binding event.

Aflibercept functions as a decoy VEGFR, binding VEGF-A across all isoforms with subpicomolar affinity...

Immediate downstream consequences: receptor phosphorylation blockade.

By sequestering free ligand, aflibercept prevents VEGF from engaging cell-surface VEGFR1 and VEGFR2...

Downstream signaling cascade: endothelial migration, proliferation, and vascular tone.

Ablation of VEGFR phosphorylation collapses downstream PI3K/Akt and MAPK signaling in endothelial cells...

Parallel pathway: PlGF and VEGF-B blockade via VEGFR1.

Aflibercept captures VEGF-B and PlGF, providing dual-axis suppression unlike other anti-VEGF-A antibodies.

Clinical translation: ocular disease and oncology.

In ophthalmology, intravitreal anti-VEGF administration lowers intraocular VEGF, reduces vascular permeability...

Clinical Relevance

Approved Indications

Key Drug Interactions (Mechanism-Based)

Warnings and Contraindications

Emerging Indications

Oncology

Neurology

Reproductive Health

Clinical Trials of Aflibercept

Trial Name Phase Design N Enrolled Indication Primary Endpoint Key Result Status
PULSAR Phase 3 randomized, non-inferiority trial 1009 Neovascular AMD Change in visual acuity (BCVA) at week 48 At 96 weeks, mean change in BCVA from baseline was +5.6 letters... Ongoing
PHOTON Phase 2/3 randomized, double-masked, non-inferiority trial 658 DME Change in BCVA at week 48 Mean BCVA change from baseline was +8.8 letters... Completed
SCORE2 Landmark Phase 3 non-inferiority RCT 362 Central Vein Occlusion Mean change in visual acuity at 6 months At 6 months, mean visual acuity letter score improved... Completed

Aflibercept Competitive Landscape

Drug Class Representative Drug(s) Primary Molecular Target Mechanism of Action Key Efficacy Outcomes Route & Dosing Safety / Risk Profile Key Limitations
VEGF-trap fusion proteins Aflibercept (Eylea, Eylea HD) VEGF-A and Placental Growth Factor (PlGF) Acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), inhibiting the binding and activation of their cognate receptors. Demonstrated improvements in visual acuity and reduced treatment frequency Intravitreal injection, typically every 4 to 8 weeks Common adverse events include conjunctival hemorrhage, eye pain... Some patients on extended dosing intervals may not maintain response.
Anti-VEGF monoclonal antibody fragments Ranibizumab, Brolucizumab VEGF-A Binds to and inhibits the biologic activity of human VEGF-A, preventing its interaction with its receptors. Mean BCVA gains across trials, specific improvements noted depending on indications Intravitreal injection, typically administered monthly Common adverse effects include conjunctival hemorrhage, eye pain Requires frequent injections to maintain efficacy.
Anti-VEGF full-length monoclonal antibodies Bevacizumab (Avastin) All VEGF-A isoforms Binds to all isoforms of VEGF-A, preventing interaction with its receptors. Improved visual acuity in comparison studies Intravitreal injection, typically every 4 weeks Higher systemic adverse event rates compared to other agents Used off-label for ophthalmic indications.

Open Research Questions